Home › Ulcerative Colitis › Massachusetts › Newton
Ulcerative Colitis clinical trials in Newton, MA
4 studies for Ulcerative Colitis are looking for participants at sites in and around Newton (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RecruitingPhase 4
- Gastro Health Research - Framingham, Framingham · 11 mi away
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
RecruitingPhase 3
- Massachusetts General Hospital, Waltham · 3 mi away
Treatment of UC With Novel Therapeutics
RecruitingPhase 2
- Brigham and Women's Hospital, Chestnut Hill · 2 mi away
Study of Novel Therapeutics for Acute Remedy of Colitis
RecruitingPhase 2
- Brigham and Women's Hospital, Chestnut Hill · 2 mi away
- Brigham and Women's Hospital, Chestnut Hill · 2 mi away
About Ulcerative Colitis
Ulcerative Colitis (UC) can cause long-lasting swelling and ulcers in the large intestine. It is a type of inflammatory bowel disease. Find out more.
More about Ulcerative Colitis on MedlinePlus
Ulcerative Colitis trials in other cities
- New York City, NY24 studies
- Orlando, FL23 studies
- Miami, FL22 studies
- Houston, TX18 studies
- San Antonio, TX16 studies
- Tacoma, WA15 studies
- Chicago, IL15 studies
- San Diego, CA15 studies
- Colorado Springs, CO14 studies
- St. Louis, MO14 studies
- Tyler, TX14 studies
- Los Angeles, CA13 studies
Other studies in Newton
- Alzheimer's Disease12 studies
- Obesity10 studies
- Major Depressive Disorder10 studies
- Depression7 studies
- Overweight6 studies
- Psoriasis6 studies
- Non-Small Cell Lung Cancer5 studies
- Schizophrenia4 studies
- Breast Cancer4 studies
- Cancer (all types)4 studies
- Chronic Pain4 studies
- Mild Cognitive Impairment4 studies
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.